India’s telecom market has narrowed to a Jio–Airtel duopoly. Here’s how price wars, scale, 5G and strategy reshaped competition and locked it in.
Today is Thursday, Feb. 5, the 36th day of 2026. There are 329 days left in the year.
The Realme P4 Power, boasting a 10,001mAh battery, is now available for purchase.
Spotify update underscores shifting role of lyrics on music-streaming services Music AllyGet More From Lyrics on Spotify With These 3 Upgrades SpotifySpotify Enhances Lyrics Feature with Offline Access and Additional Translations FilmoGazHow To Read, Translate, and Use Spotify Lyrics Offline: Step-by-Step Guide GizbotSpotify launches offline lyrics, translations, and lyric previews The Verge
The platform bridges gaps in modern parenting, offering a single ecosystem where parents can discover, participate and connect, all in one place.
Expanding the Spectrum of Uropathogens: A Rare Human Urinary Tract Infection by Rodentibacter pneumotropicus The Cureus Journal of Medical Science
Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC TAIPEI and SHANGHAI and SAN FRANCISCO, Feb. 4, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today announced a robust schedule of scientific presentations at major international oncology congresses throughout Q1 2026. The selection of multiple abstracts, including four high-profile oral presentations, underscores the clinical maturity and global scientific recognition of HanchorBio's proprietary pipeline. The upcoming presentations will feature clinical data from the Company's lead programs, including the HCB101-101 Phase 1 monotherapy (NCT05892718) and the HCB101-201 Phase 1b/2a combination (NCT06771622) studies, as well as the HCB301-101 Phase 1 monotherapy (NCT06487624) study, highlighting the therapeutic potential of its CD47-SIRPα innate immune backbone and multi-functional biologics: HCB101: A highly engineered SIRPα–IgG4 Fc-fusion protein designed to maximize phagocytosis while minimizing hematologic toxicities. HCB301: A first-in-class multi-specific candidate targeting the CD47/SIRPα, PD-1/PD-L1, and TGFb pathways to overcome the immunosuppressive tumor microenvironment (TME). "The concentration of oral and poster presentations at premier global forums like AACR-IO and ESMO-TAT reflects the significant momentum of our clinical programs," said Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (Group) and CEO (U.S.A.) of HanchorBio. "By presenting data on both HCB101 and HCB301, we are demonstrating our ability to execute our complex, multi-center trials and our commitment to delivering next-generation innate immune checkpoint therapies to patients globally." Q1 2026 Global Scientific Calendar Following the successful presentation of the high objective response rate with HCB101 combination in second-line gastric cancer from the HCB101-201 Phase 1b/2a combination study at the ASCO Gastrointestinal Cancers Symposium in January, HanchorBio continues its aggressive clinical disclosure schedule with the following upcoming presentations: Status Conference Location Date Presentation Completed ASCO GI Cancers Symposium San Francisco, USA Jan 08-10 1 Poster Upcoming AACR Immuno-Oncology Los Angeles, USA Feb 18-21 2 Posters Upcoming Asia-Pacific GI Cancer Congress Okinawa, Japan Mar 05-06 1 Poster Upcoming ESMO Targeted Anticancer Therapies Paris, France Mar 16-18 2 Orals, 1 Poster Upcoming ESMO Head and Neck Congress Seville, Spain Mar 19-21 1 Oral Upcoming World Oncology Congress Paris, France Mar 23-25 1 Oral About HCB101: A Next-Generation SIRPα Fc-Fusion Protein HCB101 is a rationally engineered SIRPα–IgG4 Fc fusion protein developed on HanchorBio's FBDBTM platform to selectively block the CD47–SIRPα innate immune checkpoint while minimizing hematologic toxicity. Unlike earlier anti-CD47 approaches, HCB101 is designed to preserve macrophage-mediated antitumor activity while reducing binding to red blood cells, a limitation that historically constrained the clinical utility of CD47-directed therapies. HCB101 was engineered using AI-assisted structural modeling to achieve differentiated binding to CD47 on cancer cells while maintaining low affinity for CD47 on red blood cells. Its safety profile, receptor occupancy characteristics, and pharmacologic properties are designed to support integration with established oncology regimens without disrupting standard dosing, safety expectations, or clinical workflows. Across ongoing clinical and translational evaluation, HCB101 has demonstrated consistent target engagement and early antitumor activity as both monotherapy and in combination settings, including tumor types historically considered challenging for CD47-directed therapies. Together, these attributes position HCB101 as a differentiated innate immune checkpoint backbone with broad potential for a wide variety of combination strategies across solid tumors and hematologic malignancies. About HCB301: A Tri-Specific Checkpoint Immunotherapy HCB301 is HanchorBio's next-generation immunotherapy designed to integrate three synergistic mechanisms into a single molecule: CD47-SIRPα blockade to activate myeloid phagocytosis, PD-1 inhibition to restore exhausted T cells, and TGF-b pathway suppression to counteract immune evasion. Developed using the proprietary FBDBTM platform, HCB301 represents a next-generation approach to multi-checkpoint immunotherapy. Preclinical studies demonstrated enhanced immune activation and potent antitumor activity, and the results were presented at the SITC 2025. About HanchorBio Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio's proprietary Fc-based designer biologics (FBDBTM) platform enables the design of multi-functional biologics with diverse targeting modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDBTM platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies. For more information, please visit: https://www.HanchorBio.com
A new study shows that lipid nanoparticles restructure their membrane significantly after being absorbed into a cell and ending up in an acidic environment.
Researchers developed a fingertip-sized, humidity-tolerant hydrogen sensor using platinum nanoparticles that catalyze reactions, thin a water film, change color, and trigger alarms.
Earth hit by geomagnetic storm QazinformRed Aurora in Ladakh Explained: What Caused This Rare Phenomenon Open MagazineWhen The Sky Turned Crimson: Hanle’s Rare Celestial Moment Explained News18Solar radiation storm hits S4. Risks for satellites. Holistic NewsThe Geomagnetic Storm That Sparked Panic Across a Continent Nautilus | Science Connected
WhatsApp Business could potentially start charging users who want to link more than four devices to the same account in a future update.
A bug in Google Messages is causing severe battery drain and overheating on some devices. Here's a temporary fix while you wait for Google to push an update.
Redmi 10 Power Price in India: Redmi has launched its new smartphone Redmi 10 Power in India. The smartphone was launched along with Redmi 10A, on Wednesday, 20 April in India
The premium Alienware m15 R7 and m17 R5 highlight four new Ryzen-powered systems.
Apple is offering its new firmware update for the MagSafe accessory that promises to give you faster charging for the compatible iPhone models.
System apps with native call-recording functionality remain unaffected.
The OnePlus Nord 2T India launch may take place soon as the moniker has been spotted on the TDRA certification. The OnePlus Nord 2T's camera details have also been leaked. Here are the expected specifications of the device.
The iPhone 16 is likely to be the first Apple device to skip the camera notch.
Garena Free Fire Max redeem codes are 12-digit codes that are region-specific and can be used by players to gain an edge over rivals in every round of the battle royale game.
We are still not sure that no-charger policy will be limited to Narzo 50A Prime or it will be extended to other Realme budget, mid-segment and premium phones
